Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentane SCHEMBL2525553 | 0.96 | TSHR (0.64) | TSHRLMNATHRBALDH1A1TDP1 | |
| Pentane SCHEMBL1825700 | 0.92 | TSHR (0.58) | TSHRLMNATHRBALDH1A1TDP1 | |
| Octane SCHEMBL19915290 | 0.88 | TSHR (0.61) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Hexane SCHEMBL29124909 | 0.87 | TSHR (0.58) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Hexane SCHEMBL27826796 | 0.87 | TSHR (0.58) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Octane SCHEMBL27625 | 0.83 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Octane SCHEMBL27624 | 0.83 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Undecane SCHEMBL28453375 | 0.83 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Heptane SCHEMBL28681950 | 0.83 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Heptane SCHEMBL28458543 | 0.83 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366778-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | Bright Peak Therapeutics AG (CH) | 2024-05-15 | — | — | EP | claimed |
| CN-117615793-A | Antibody conjugates and their preparation | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117337196-A | Pegylated antibody hydroxyl-containing drug conjugates | 深圳康源久远生物技术有限公司 | 2024-01-02 | — | — | CN | claimed |
| WO-2023281481-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS (CH) | 2023-01-12 | — | — | WO | claimed |
| CN-113150018-A | Four-coordination N, N-chelating monoaryl monofluoroborate compound and preparation method thereof | 石河子大学 | 2021-07-23 | — | — | CN | claimed |
| CN-112592260-A | Method for synthesizing cannabidiol | 云南苏理生物医药科技有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-108203440-B | Solvent-free double-screw extrusion continuous synthesis process of potassium aryl trifluoroborate | 华东师范大学 | 2020-08-25 | — | — | CN | claimed |
| CN-108218717-B | Method for preparing asymmetric terphenyl compound by using bromoarylsulfonyl fluoride | 遵义医科大学 | 2020-01-07 | — | — | CN | claimed |
| CN-117945858-A | Synthesis method of cannabidiol, intermediate and preparation method thereof | 南京派康医疗科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240132563-A1 | BIFUNCTIONAL CYTOKINE COMPOSITIONS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20240116997-A1 | ACTIVATABLE IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-04-11 | — | — | US | disclosed |
| CN-117616036-A | Modified IL-2 polypeptides for the treatment of inflammatory and autoimmune diseases | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117337196-A | Pegylated antibody hydroxyl-containing drug conjugates | 深圳康源久远生物技术有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| US-7501510-B2 | Thiourea compositions and uses thereof | THE UNIVERSITY OF HONG KONG (CN) | 2009-03-10 | — | — | US | disclosed |
| WO-2008119162-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| EP-1730117-A4 | THIOUREA COMPOSITIONS AND USES THEREOF | UNIV HONG KONG (CN) | 2008-07-02 | — | — | EP | disclosed |
| EP-1730117-A2 | THIOUREA COMPOSITIONS AND USES THEREOF | The University of Hong Kong (CN) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005091697-A2 | THIOUREA COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215783-A1 | Thiourea compositions and uses thereof | UNIVERSITY OF HONG KONG, THE (HK) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116997-A1 | ACTIVATABLE IL-18 POLYPEPTIDES | IL18, IL36G, CXCL8 | TSHR 1473/4885LMNA 3432/4885THRB 2636/4885 |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | TSHR 981/4885LMNA 2550/4885THRB 1164/4885 |
| US-20050215783-A1 | Thiourea compositions and uses thereof | DDT, ITK, DTYMK | TSHR 367/4885LMNA 4874/4885THRB 408/4885 |
| US-20240132563-A1 | BIFUNCTIONAL CYTOKINE COMPOSITIONS | IL2, IL17A, IL2RA | TSHR 3599/4885LMNA 4679/4885THRB 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.